Micafungin

Evidence Level: L3

Predicted Indications: 10

Micafungin
Micafungin: From Candidemia and Invasive Candidiasis to Urinary Tract Infection (Candida)

## Pharmacist Assessment Report

Micafungin: From Candidemia and Invasive Candidiasis to Urinary Tract Infection (Candida)

One-Sentence Summary

Micafungin is an echinocandin antifungal, originally used to treat esophageal candidiasis, candidemia and disseminated candidiasis. The TxGNN model predicts it may be effective for urinary tract infection, and the data compiled for this report include no registered clinical trials but 12 publications. These are mostly cohort studies, case reports and case series, and they point specifically to Candida (fungal) urinary infection.

Quick Overview

Item	Content
Original Indication	Esophageal candidiasis, candidemia, disseminated candidiasis (the Singapore licence record contains no approved indication text)
Predicted New Indication	Urinary tract infection (disease)
TxGNN Prediction Score	99.03%
Evidence Level	L3
Singapore Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Micafungin belongs to the echinocandin class, which inhibits 1,3-beta-D-glucan synthase, an enzyme essential for building the fungal cell wall. It has established activity against Candida species.

Candida is a common cause of fungal urinary tract infection and candiduria. The prediction is therefore best read as an extension of micafungin's approved anti-Candida use to the urinary tract, not as a new mechanism. It applies to Candida UTI only, not to bacterial UTI.

There is one pharmacokinetic caveat. Only a small fraction of micafungin is excreted in urine, and echinocandins are not routinely recommended for candiduria. However, a pharmacokinetic report (PMID 27424599) found urinary micafungin levels sufficient to treat Candida UTI in six patients, including four with fluconazole-resistant organisms. This partly addresses the concern, but the data are small-scale.

Other predicted indications (Ureaplasma urethritis, gonococcal urethritis, uterine inflammatory disease, xanthogranulomatous pyelonephritis, urogenital tuberculosis, and several mesothelioma types) have no mechanistic basis. Most are bacterial or oncologic conditions, and the predictions appear to be knowledge-graph artifacts. They are rated Hold.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35146837	2022	Cohort	Pediatr Int	Outcomes of micafungin for hospital-acquired Candida UTI in critically ill children, including success rates by species
27587066	2016	Cohort	Int Urol Nephrol	Rates of candiduria elimination in hospitalised patients treated with micafungin
27424599	2016	Pharmacokinetic study	Int J Antimicrob Agents	Six UTI cases treated successfully; urinary micafungin levels were sufficient despite low urinary excretion
26937340	2016	Case series	Med Mycol Case Rep	Five candiduria cases treated with parenteral micafungin for at least 6 days; all cleared within 30 days of completion
31111613	2019	Case report	Transpl Infect Dis	Chronic symptomatic C. krusei UTI eradicated with increased-dose micafungin in a liver and kidney transplant recipient
38827222	2024	Case report	Front Pediatr	C. glabrata urinary infection treated with micafungin in a premature neonate
40765059	2025	Case report	J Pharm Health Care Sci	C. glabrata pyelonephritis and bacteraemia in a patient on an SGLT2 inhibitor, successfully treated with micafungin
38681664	2024	Case report	Med Mycol Case Rep	Unilateral renal fungus ball from C. glabrata, treated with antifungal therapy plus endoscopic extraction; isolate was micafungin-sensitive
29109159	2018	Cohort	Antimicrob Agents Chemother	Multi-centre study showing overtreatment of asymptomatic candiduria; guidelines advise against antifungals in that setting

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN14464P	MYCAMINE POWDER FOR SOLUTION FOR INFUSION 50MG/VIAL	Lyophilised powder for injection (solution for infusion)	Approved indication text not available in the licence record

Safety Considerations

Contraindications (knowledge-graph association, not label text): Kidney disease and pyoureter are linked to micafungin in the knowledge graph. This matters for a urinary indication, so renal function and the urinary tract should be assessed before use.
Drug Interactions (5 moderate-level interactions): Amphotericin B, nitisinone, everolimus, ribociclib and sirolimus.

For other warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The Candida UTI signal is mechanistically plausible and is supported by several cohort studies, a pharmacokinetic study and multiple case reports. However, there are no registered clinical trials and no RCTs, and the evidence is observational (L3). The low urinary excretion of micafungin remains a concern. The use should be limited to Candida UTI or candiduria, particularly fluconazole-resistant or non-albicans infections, and not extended to bacterial UTI. The other nine predictions are rated Hold because they lack any supporting evidence.

To proceed, the following is needed:

Review of the Singapore package insert (warnings, contraindications and approved indications) for safety screening
Detailed mechanism of action data from DrugBank
Prospective or comparative clinical data on Candida UTI, ideally including urinary pharmacokinetics and microbiological cure rates
A patient-selection policy that separates symptomatic Candida UTI from asymptomatic candiduria, which generally should not be treated
Renal function assessment and a drug-interaction review before use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.